^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    VEGF-A inhibitor

    Related drugs:
    1d
    AMBITION: A Phase III Study of Bevacizumab and Paclitaxel in Combination With Atezolizumab as a Treatment for Locally Advanced Unresectable or Metastatic Hormone Receptor-positive HER2 Negative Breast Cancer (clinicaltrials.gov)
    P3, N=281, Completed, Japanese Foundation for Cancer Research | Trial completion date: Sep 2025 --> Mar 2026 | Active, not recruiting --> Completed
    Trial completion • Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    HR positive • HER-2 negative
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • paclitaxel
    1d
    ML41701: A Phase II Study of Atezolizumab in Combination With Bevacizumab, Carboplatin or Cisplatin, and Pemetrexed for EGFR-mutant Metastatic Non-small Cell Lung Cancer Patients After Failure of EGFR Tyrosine Kinase Inhibitors. (clinicaltrials.gov)
    P2, N=22, Completed, National Taiwan University Hospital | Active, not recruiting --> Completed | Trial completion date: Dec 2024 --> Feb 2026 | Trial primary completion date: Dec 2024 --> Feb 2026
    Trial completion • Trial completion date • Trial primary completion date • IO biomarker
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR G719X • EGFR S768I
    |
    Avastin (bevacizumab) • cisplatin • Tecentriq (atezolizumab) • carboplatin • pemetrexed
    1d
    NIBCUN: Neoadjuvant IBI308, Bevacizumab, Plus Pemetrexed and Carboplatin Followed by Surgery in Unresectable Stage III NSCLC (clinicaltrials.gov)
    P2, N=36, Recruiting, Sun Yat-sen University | Trial completion date: Dec 2026 --> Dec 2029 | Trial primary completion date: Dec 2025 --> Dec 2029
    Trial completion date • Trial primary completion date
    |
    Avastin (bevacizumab) • carboplatin • Tyvyt (sintilimab) • pemetrexed
    1d
    BEATcc: Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix (clinicaltrials.gov)
    P3, N=410, Completed, Grupo Español de Investigación en Cáncer de Ovario | Active, not recruiting --> Completed
    Trial completion
    |
    Avastin (bevacizumab) • cisplatin • Tecentriq (atezolizumab) • carboplatin • paclitaxel
    2d
    Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients (clinicaltrials.gov)
    P2/3, N=156, Recruiting, Sun Yat-sen University | Trial completion date: Dec 2028 --> Dec 2029
    Trial completion date • pMMR
    |
    BRAF (B-raf proto-oncogene) • RAS (Rat Sarcoma Virus)
    |
    BRAF wild-type
    |
    Avastin (bevacizumab) • 5-fluorouracil • oxaliplatin • leucovorin calcium • Hetronifly (serplulimab)
    3d
    Atezolizumab for Alveolar Soft Part Sarcoma: A Clinical Trial Update. (PubMed, J Clin Oncol)
    Nine eligible patients elected to receive bevacizumab plus atezolizumab after progressing on monotherapy; ORR was 0% and mPFS was 18.5 months (IQR, 7.9-21.1) in this small cohort. Long-term results support using atezolizumab to treat ASPS, even for several years; a drug holiday with careful monitoring may be an option for some patients.
    Journal
    |
    TFE3 (Transcription Factor Binding To IGHM Enhancer 3) • ASPSCR1 (ASPSCR1 Tether For SLC2A4)
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab)
    3d
    IFCT-2502: Trial assessing treatment in patients with advanced Lung Cancer and Interstitial Lung Disease (2025-522790-10-00)
    P1/2, N=108, Not yet recruiting, Intergroupe Francophone De Cancerologie Thoracique
    New P1/2 trial
    |
    IFIH1 (Interferon Induced With Helicase C Domain 1)
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • carboplatin • gemcitabine • paclitaxel • pemetrexed • vinorelbine tartrate
    4d
    Lactate-induced lactylation enhances BMAL1 transcription and nuclear translocation, promoting bevacizumab resistance in glioblastoma through VEGFA. (PubMed, Clin Cancer Res)
    These findings reveal a novel mechanism through which lactate-mediated lactylation of BMAL1 promotes Bev resistance in GBM, supporting the lactate/BMAL1/TUBA1C/VEGFA axis as a promising therapeutic target for overcoming Bev resistance in GBM patients.
    Journal
    |
    VEGFA (Vascular endothelial growth factor A) • ARNTL (Aryl Hydrocarbon Receptor Nuclear Translocator Like) • TUBA1C (Tubulin Alpha 1c)
    |
    Avastin (bevacizumab)
    5d
    Baseline and dynamic cytokines as biomarkers for immune checkpoint and anti-VEGF therapy in advanced hepatocellular carcinoma. (PubMed, ESMO Gastrointest Oncol)
    Among 56 enrolled patients, 35 patients were treated with ICIs only (ICI-only), and 21 patients were treated with ICIs plus the VEGF inhibitor bevacizumab (ICI + Bev)...In a highly exploratory analysis, myeloid-inflammatory signatures at baseline and treatment-associated reductions in key myeloid cytokines may identify patients most likely to benefit from adding Bev to ICI. Prospective validation of these markers in independent cohorts is warranted.
    Journal • IO biomarker
    |
    IFNG (Interferon, gamma) • IL6 (Interleukin 6) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • CCL4 (Chemokine (C-C motif) ligand 4) • IL18 (Interleukin 18) • CD40LG (CD40 ligand) • IL1R1 (Interleukin 1 receptor, type I)
    |
    Avastin (bevacizumab)
    5d
    Bevacizumab/Doxorubicin/Radiation for Sarcoma (clinicaltrials.gov)
    P1, N=14, Active, not recruiting, Massachusetts General Hospital | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    |
    Avastin (bevacizumab) • doxorubicin hydrochloride
    5d
    BEST: SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2, N=58, Not yet recruiting, Shanghai Zhongshan Hospital
    New P2 trial • Tumor mutational burden • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    Avastin (bevacizumab) • Tyvyt (sintilimab) • Stivarga (regorafenib) • Lonsurf (trifluridine/tipiracil)